NCT04846959 - Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications | Biotech Hunter

Enrollment

818

Participants

Timeline

Start Date

July 30, 2021

Primary Completion Date

June 30, 2032

Study Completion Date

June 30, 2032

Conditions

Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease, or Other Conditions for Which Risankizumab is an FDA-approved Treatment

Interventions

DRUG

Risankizumab

Subcutaneous Injection

DRUG

Comparator

Subcutaneous or Intravenous Injection

Trial Locations (2)

RECRUITING

Evidera, a PPD Business Unit /ID# 238688, Morrisville

COMPLETED

PPD Development, LP /ID# 232134, Wilmington